XML 92 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
EARNINGS (LOSS) PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2014
Earnings Per Share [Abstract]  
Schedule of calculation of earnings per share
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and nine-month periods ended September 30, 2014 and 2013 were calculated as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2014
 
2013
 
2014
 
2013
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.
$
275.4

 
$
(973.2
)
 
$
378.6

 
$
(989.9
)
 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
335.4

 
333.6

 
335.2

 
316.5

Diluted effect of stock options and RSUs(a)
5.9

 
—

 
6.2

 
—

Diluted weighted-average number of common shares outstanding
341.3

 
333.6

 
341.4

 
316.5

 
 
 
 
 
 
 
 
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
0.82

 
$
(2.92
)
 
$
1.13

 
$
(3.13
)
Diluted
$
0.81

 
$
(2.92
)
 
$
1.11

 
$
(3.13
)
____________________________________
(a)
In the three-month and nine-month periods ended September 30, 2013, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months
Ended
September 30,
 
Nine Months
Ended
September 30,
 
 
2013
 
2013
Basic weighted-average number of common shares outstanding
 
333.6

 
316.5

Dilutive effect of stock options and RSUs
 
6.6

 
6.4

Diluted weighted-average number of common shares outstanding
 
340.2

 
322.9
Schedule of dilutive effect of stock options, RSUs and Convertible Notes on weighted-average number of common shares outstanding
The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months
Ended
September 30,
 
Nine Months
Ended
September 30,
 
 
2013
 
2013
Basic weighted-average number of common shares outstanding
 
333.6

 
316.5

Dilutive effect of stock options and RSUs
 
6.6

 
6.4

Diluted weighted-average number of common shares outstanding
 
340.2

 
322.9